Pharma industry seeks court ruling on NICE drugs price cap

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

British pharmaceutical companies are taking the National Institute for Health and Care Excellence (NICE) to court over the watchdog’s policy of capping funding at £20 million.

Under NICE’s policy, funding could be delayed or restricted for any drug that costs the NHS more than £20 million ...